Literature DB >> 22761364

Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock.

Penny A Rudd1, Jane Wilson, Joy Gardner, Thibaut Larcher, Candice Babarit, Thuy T Le, Itaru Anraku, Yutaro Kumagai, Yueh-Ming Loo, Michael Gale, Shizuo Akira, Alexander A Khromykh, Andreas Suhrbier.   

Abstract

Chikungunya virus (CHIKV) infections can produce severe disease and mortality. Here we show that CHIKV infection of adult mice deficient in interferon response factors 3 and 7 (IRF3/7(-/-)) is lethal. Mortality was associated with undetectable levels of alpha/beta interferon (IFN-α/β) in serum, ∼50- and ∼10-fold increases in levels of IFN-γ and tumor necrosis factor (TNF), respectively, increased virus replication, edema, vasculitis, hemorrhage, fever followed by hypothermia, oliguria, thrombocytopenia, and raised hematocrits. These features are consistent with hemorrhagic shock and were also evident in infected IFN-α/β receptor-deficient mice. In situ hybridization suggested CHIKV infection of endothelium, fibroblasts, skeletal muscle, mononuclear cells, chondrocytes, and keratinocytes in IRF3/7(-/-) mice; all but the latter two stained positive in wild-type mice. Vaccination protected IRF3/7(-/-) mice, suggesting that defective antibody responses were not responsible for mortality. IPS-1- and TRIF-dependent pathways were primarily responsible for IFN-α/β induction, with IRF7 being upregulated >100-fold in infected wild-type mice. These studies suggest that inadequate IFN-α/β responses following virus infection can be sufficient to induce hemorrhagic fever and shock, a finding with implications for understanding severe CHIKV disease and dengue hemorrhagic fever/dengue shock syndrome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22761364      PMCID: PMC3446587          DOI: 10.1128/JVI.00956-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells.

Authors:  A Vecchi; L Massimiliano; S Ramponi; W Luini; S Bernasconi; R Bonecchi; P Allavena; M Parmentier; A Mantovani; S Sozzani
Journal:  J Leukoc Biol       Date:  1999-09       Impact factor: 4.962

2.  Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection.

Authors:  L P Cousens; J S Orange; H C Su; C A Biron
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

3.  Dengue virus replication in infected human keratinocytes leads to activation of antiviral innate immune responses.

Authors:  Pornapat Surasombatpattana; Rodolphe Hamel; Sirilaksana Patramool; Natthanej Luplertlop; Frédéric Thomas; Philippe Desprès; Laurence Briant; Hans Yssel; Dorothée Missé
Journal:  Infect Genet Evol       Date:  2011-06-21       Impact factor: 3.342

4.  Chikungunya disease.

Authors:  J J Deller; P K Russell
Journal:  Am J Trop Med Hyg       Date:  1968-01       Impact factor: 2.345

5.  Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling.

Authors:  Jelke J Fros; Wen Jun Liu; Natalie A Prow; Corinne Geertsema; Maarten Ligtenberg; Dana L Vanlandingham; Esther Schnettler; Just M Vlak; Andreas Suhrbier; Alexander A Khromykh; Gorben P Pijlman
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

6.  The naturally attenuated Kunjin strain of West Nile virus shows enhanced sensitivity to the host type I interferon response.

Authors:  Stephane Daffis; Helen M Lazear; Wen Jun Liu; Michelle Audsley; Michael Engle; Alexander A Khromykh; Michael S Diamond
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

7.  Type I IFN controls chikungunya virus via its action on nonhematopoietic cells.

Authors:  Clémentine Schilte; Thérèse Couderc; Fabrice Chretien; Marion Sourisseau; Nicolas Gangneux; Florence Guivel-Benhassine; Anton Kraxner; Jürg Tschopp; Stephen Higgs; Alain Michault; Fernando Arenzana-Seisdedos; Marco Colonna; Lucie Peduto; Olivier Schwartz; Marc Lecuit; Matthew L Albert
Journal:  J Exp Med       Date:  2010-02-01       Impact factor: 14.307

8.  Dengue and chikungunya virus infection in man in Thailand, 1962-1964. I. Observations on hospitalized patients with hemorrhagic fever.

Authors:  S Nimmannitya; S B Halstead; S N Cohen; M R Margiotta
Journal:  Am J Trop Med Hyg       Date:  1969-11       Impact factor: 2.345

Review 9.  Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes.

Authors:  Scott B Halstead; Suresh Mahalingam; Mary A Marovich; Sukathida Ubol; David M Mosser
Journal:  Lancet Infect Dis       Date:  2010-10       Impact factor: 25.071

10.  Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts.

Authors:  Sandeep K Agarwal; Minghua Wu; Christopher K Livingston; Donald H Parks; Maureen D Mayes; Frank C Arnett; Filemon K Tan
Journal:  Arthritis Res Ther       Date:  2011-01-11       Impact factor: 5.156

View more
  79 in total

1.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

2.  Distinct Roles of Interferon Alpha and Beta in Controlling Chikungunya Virus Replication and Modulating Neutrophil-Mediated Inflammation.

Authors:  Lindsey E Cook; Marissa C Locke; Alissa R Young; Kristen Monte; Matthew L Hedberg; Raeann M Shimak; Kathleen C F Sheehan; Deborah J Veis; Michael S Diamond; Deborah J Lenschow
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

3.  A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

Authors:  Juan García-Arriaza; Victoria Cepeda; David Hallengärd; Carlos Óscar S Sorzano; Beate Mareike Kümmerer; Peter Liljeström; Mariano Esteban
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

4.  The Intestinal Microbiome Restricts Alphavirus Infection and Dissemination through a Bile Acid-Type I IFN Signaling Axis.

Authors:  Emma S Winkler; Swathi Shrihari; Barry L Hykes; Scott A Handley; Prabhakar S Andhey; Yan-Jang S Huang; Amanda Swain; Lindsay Droit; Kranthi K Chebrolu; Matthias Mack; Dana L Vanlandingham; Larissa B Thackray; Marina Cella; Marco Colonna; Maxim N Artyomov; Thaddeus S Stappenbeck; Michael S Diamond
Journal:  Cell       Date:  2020-07-14       Impact factor: 41.582

Review 5.  Animal Models of Chikungunya Virus Infection and Disease.

Authors:  Nicole N Haese; Rebecca M Broeckel; David W Hawman; Mark T Heise; Thomas E Morrison; Daniel N Streblow
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

6.  DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.

Authors:  Irina Tretyakova; Jason Hearn; Eryu Wang; Scott Weaver; Peter Pushko
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

7.  The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus.

Authors:  Hui-Wen Chen; Kevin King; Jui Tu; Marisa Sanchez; Andrew D Luster; Sujan Shresta
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

8.  CD8+ T cells control Ross River virus infection in musculoskeletal tissues of infected mice.

Authors:  Kristina S Burrack; Stephanie A Montgomery; Dirk Homann; Thomas E Morrison
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

9.  An IRF-3-, IRF-5-, and IRF-7-Independent Pathway of Dengue Viral Resistance Utilizes IRF-1 to Stimulate Type I and II Interferon Responses.

Authors:  Aaron F Carlin; Emily M Plummer; Edward A Vizcarra; Nicholas Sheets; Yunichel Joo; William Tang; Jeremy Day; Jay Greenbaum; Christopher K Glass; Michael S Diamond; Sujan Shresta
Journal:  Cell Rep       Date:  2017-11-07       Impact factor: 9.423

10.  An essential role of antibodies in the control of Chikungunya virus infection.

Authors:  Fok-Moon Lum; Teck-Hui Teo; Wendy W L Lee; Yiu-Wing Kam; Laurent Rénia; Lisa F P Ng
Journal:  J Immunol       Date:  2013-05-13       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.